On 15 November 2024, the U.S. FDA approved revumenib (SNDX-5613, brand name: Revuforj), developed by Syndax Pharmaceuticals, as the first menin inhibitor for treating relapsed or refractory (R/R) acute leukemia in adults and pediatric patients aged one year and older with KMT2A translocations [172]. This evidence concerns the gene MEN1 and acute leukemia.